全文获取类型
收费全文 | 7035篇 |
免费 | 503篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 80篇 |
儿科学 | 200篇 |
妇产科学 | 257篇 |
基础医学 | 892篇 |
口腔科学 | 112篇 |
临床医学 | 887篇 |
内科学 | 1250篇 |
皮肤病学 | 133篇 |
神经病学 | 580篇 |
特种医学 | 190篇 |
外国民族医学 | 1篇 |
外科学 | 1122篇 |
综合类 | 102篇 |
一般理论 | 3篇 |
预防医学 | 701篇 |
眼科学 | 131篇 |
药学 | 390篇 |
中国医学 | 6篇 |
肿瘤学 | 512篇 |
出版年
2023年 | 54篇 |
2022年 | 72篇 |
2021年 | 191篇 |
2020年 | 126篇 |
2019年 | 193篇 |
2018年 | 214篇 |
2017年 | 136篇 |
2016年 | 172篇 |
2015年 | 160篇 |
2014年 | 263篇 |
2013年 | 339篇 |
2012年 | 490篇 |
2011年 | 478篇 |
2010年 | 261篇 |
2009年 | 227篇 |
2008年 | 389篇 |
2007年 | 366篇 |
2006年 | 356篇 |
2005年 | 343篇 |
2004年 | 284篇 |
2003年 | 286篇 |
2002年 | 290篇 |
2001年 | 129篇 |
2000年 | 145篇 |
1999年 | 114篇 |
1998年 | 51篇 |
1997年 | 40篇 |
1996年 | 29篇 |
1995年 | 47篇 |
1994年 | 25篇 |
1993年 | 31篇 |
1992年 | 82篇 |
1991年 | 87篇 |
1990年 | 77篇 |
1989年 | 83篇 |
1988年 | 70篇 |
1987年 | 79篇 |
1986年 | 72篇 |
1985年 | 70篇 |
1984年 | 52篇 |
1983年 | 68篇 |
1982年 | 43篇 |
1981年 | 41篇 |
1980年 | 37篇 |
1979年 | 52篇 |
1978年 | 30篇 |
1974年 | 41篇 |
1973年 | 25篇 |
1972年 | 32篇 |
1969年 | 27篇 |
排序方式: 共有7549条查询结果,搜索用时 15 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
3.
4.
Leah H. Cobb Emily M. McCabe Lauren B. Priddy 《Journal of orthopaedic research》2020,38(10):2091-2103
Osteomyelitis, or the infection of the bone, presents a major complication in orthopedics and may lead to prolonged hospital visits, implant failure, and in more extreme cases, amputation of affected limbs. Typical treatment for this disease involves surgical debridement followed by long-term, systemic antibiotic administration, which contributes to the development of antibiotic-resistant bacteria and has limited ability to eradicate challenging biofilm-forming pathogens including Staphylococcus aureus—the most common cause of osteomyelitis. Local delivery of high doses of antibiotics via traditional bone cement can reduce systemic side effects of an antibiotic. Nonetheless, growing concerns over burst release (then subtherapeutic dose) of antibiotics, along with microbial colonization of the nondegradable cement biomaterial, further exacerbate antibiotic resistance and highlight the need to engineer alternative antimicrobial therapeutics and local delivery vehicles with increased efficacy against, in particular, biofilm-forming, antibiotic-resistant bacteria. Furthermore, limited guidance exists regarding both standardized formulation protocols and validated assays to predict efficacy of a therapeutic against multiple strains of bacteria. Ideally, antimicrobial strategies would be highly specific while exhibiting a broad spectrum of bactericidal activity. With a focus on S. aureus infection, this review addresses the efficacy of novel therapeutics and local delivery vehicles, as alternatives to the traditional antibiotic regimens. The aim of this review is to discuss these components with regards to long bone osteomyelitis and to encourage positive directions for future research efforts. 相似文献
5.
R. Watson T. Kozlowski V. Nickeleit J. T. Woosley J. L. Schmitz S. L. Zacks J. H. Fair D. A. Gerber K. A. Andreoni 《American journal of transplantation》2006,6(12):3022-3029
Antibody-mediated rejection (AMR) after liver transplantation is recognized in ABO incompatible and xeno-transplantation, but its role after ABO compatible liver transplantation is controversial. We report a case of ABO compatible liver transplantation that demonstrated clinical, serological and histological signs of AMR without evidence of concurrent acute cellular rejection. AMR with persistently high titers of circulating donor specific antibodies resulted in graft injury with initial centrilobular hepatocyte necrosis, fibroedematous portal expansion mimicking biliary tract outflow obstruction, ultimately resulting in extensive bridging fibrosis. Immunofluorescence microscopy demonstrated persistent, diffuse linear C4d deposits along sinusoids and central veins. Despite intense therapeutic intervention including plasmapheresis, IVIG and rituximab, AMR led to graft failure. We present evidence that an antibody-mediated alloresponse to an ABO compatible liver graft can cause significant graft injury independent of acute cellular rejection. AMR shows distinct histologic changes including a characteristic staining profile for C4d. 相似文献
6.
7.
Since 1987, 80 hydroxyapatite-coated (HA) cementless total hip prostheses have been implanted. Thirty patients were examined 21 months postoperatively and the results compared with data for uncoated prosthesis. Earlier mobilization and freedom from pain, together with evidence of bone ingrowth without connective tissue membrane formation, confirmed the benefits of HA-coated prostheses. 相似文献
8.
9.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
10.